We are pleased to announce the publication of a new white paper co-authored by Cilcare and CBSET, featured in World Pharma Today, titled: "Gene Therapy for Hearing Loss: A Translational…
Cilcare is proud to mark a decade of groundbreaking work in hearing loss and tinnitus research. Since our founding in 2014, we have remained committed to driving scientific innovation and…
In the intricate realm of drug development, safeguarding auditory function emerges as a paramount concern. The threat of ototoxicity—a condition characterized by drug-induced damage to the ear—poses significant challenges in…
In a groundbreaking article by Clare Wilson on NewScientist, a new understanding on tinnitus and deafness emerges, promising potential breakthroughs in treatment.Tinnitus, characterized by persistent ringing or buzzing in the…
Expanded partnership with academic and public US and French institutions, with University of Vermont Health Network and ARIS (Agence Régionale Investissements Stratégiques) now among our shareholders, to enhance our innovation…
We are excited to announce our feature in the prestigious MedNous journal, as highlighted by Jean-Claude Müller. This publication, stemming from insightful discussions at the J.P. Morgan conference, delves into…
In the quest to understand complex neurological conditions like autism, schizophrenia, and Alzheimer's disease, researchers from Cilcare in collaboration with Pasteur Institute leverage innovative techniques to detect central auditory processing…
